Phase 1 Recurrent Malignant Glioma Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Phase 1
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Recurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaRecurrent Malignant Glioma+3 more
Ohio State University Comprehensive Cancer Center30 enrolled1 locationNCT06964737
Recruiting
Phase 1
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
GlioblastomaMalignant GliomaRecurrent Glioblastoma+3 more
Sabine Mueller, MD, PhD20 enrolled20 locationsNCT04323046